Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487345 | 1.00 | MAPK1 (0.46) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3487146 | 0.90 | L3MBTL1 (0.44) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3488705 | 0.90 | SMN1; SMN2 (0.47) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3487141 | 0.90 | L3MBTL1 (0.44) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3488709 | 0.90 | SMN1; SMN2 (0.47) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3487363 | 0.90 | HSPB1 (0.45) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3487359 | 0.90 | HSPB1 (0.45) | MAPK1HTTSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3487984 | 0.89 | NPSR1 (0.43) | SMN1; SMN2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3487979 | 0.89 | NPSR1 (0.43) | SMN1; SMN2MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3487488 | 0.88 | MAPK1 (0.45) | MAPK1HTTSMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | MAPK1 1347/4885HTT 1560/4885SMN1; SMN2 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.